Overview Fundamentals Financials Technicals Corporate Action Shareholding Pattern Peer Comparison News Stock Analysis About Company FAQs

Natco Pharma Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

NSE: NATCOPHARM Small Cap ISIN: INE987B01026
As on 22 January 2025 at 15:59 IST
As on 22 January 2025 at 15:59 IST
1,262.85
+ 19.85
(1.60%)
About Natco Pharma Ltd

Natco Pharma Ltd, founded in the year 1981, is a vertically integrated pharmaceutical company. It specialises in finished dosage formulations and active pharmaceutical ingredients. Headquartered in Hyderabad, Telangana, the company has carved a niche in complex products and therapeutic areas, particularly oncology. From modest beginnings, Natco has become a key player in the pharmaceutical industry, serving domestic and international markets. Beyond pharmaceuticals, the company has diversified into agrochemicals, offering crop health sciences products. It is not the top stock in the pharmaceutical sector. However, Natco Pharma maintains a robust market position. Read More...

Over 1 Month
-10.48%
Over 6 Months
1.32%
Over 1 Year
47.94%
Over 3 Years
38.51%

Natco Pharma Ltd Summary

Close ₹ 1,262.85
Open ₹ 1,253.45
High ₹ 1,269.95
Low ₹ 1,233.30
Volume 4,35,619
Net Turnover (in ₹) ₹ 29,76,66,873.70
52Wk High ₹ 1,639
52Wk Low ₹ 828
52Wk High / Low
828
1,639

Natco Pharma Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 22,263.36
EPS (TTM) 102.65
Book Value (BV) 382.03
Div. Yield 0.76 %
P/E (TTM) 12.11
Price/Book Value 3.25
Delivery % 47.20 %
Face Value 2

Key Ratios

PE Ratio 13.04
PB Ratio 3.05
EV to Sales 4.64
PEG Ratio 0.12
ROA 21.66
ROE 25.38
Debt-Equity 0.05
Net Profit Margin 36.61
Operating Profit Margin 48.80

Natco Pharma Ltd Financials

Profit and Loss

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2021FY 2020
Total Revenue4,126.902,811.702,043.802,155.702,022.40
Total Expenses2,453.401,949.801,841.601,576.101,453.70
Profit Before Tax1,673.50861.90202.20579.60568.70
Profit After Tax1,388.30715.30170442.40458.10
Operating Profit after Depreciation1,692.70876.40219.90592.90590.20

Balance Sheet

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2021FY 2020
Fixed Assets2,490.802,426.902,311.802,023.201,584.40
Total Non Current Assets2,882.802,657.102,622.402,447.102,262.20
Total Current Assets4,023.503,000.302,486.702,344.802,325.60
TOTAL ASSETS6,906.305,657.405,109.104,791.904,587.80
Total Shareholder's Fund5,853.104,873.804,263.604,121.603,773.50

Cash Flow

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash from Operating Activities1,211.60849.1046.50298.80417.30
Net Cash used in Investing Activities-1,026.20-465.304-107.10-175
Net Cash used in Financing Activities-246.90-36334.80-185.70-250.80

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2021FY 2020
Total Revenue3,673.602,436.501,862.401,754.601,914
Total Expenses2,118.301,665.801,706.501,362.401,330.90
Profit Before Tax1,555.30770.70155.90392.20583.10
Profit After Tax1,306.60637.10139.10309.50474.50
Operating Profit after Depreciation1,569.80779.30169.20403.50603.70

Balance Sheet

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2021FY 2020
Fixed Assets2,286.702,233.802,174.202,005.901,574.50
Total Non Current Assets3,143.602,893.202,810.302,5842,406.80
Total Current Assets3,410.402,494.702,167.702,168.502,239.90
TOTAL ASSETS6,5545,387.904,9784,752.504,646.70
Total Shareholder's Fund5,592.304,7024,191.904,091.103,869.50

Cash Flow

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash from Operating Activities1,196.40784.4057.70183.50422.50
Net Cash used in Investing Activities-960.50-436.60-92.50-3.20-165
Net Cash used in Financing Activities-237.30-346.8035.60-183.10-261.10

Particulars (in ₹ Cr.) 2024-09 2024-06 2024-03 2023-12 2023-09
Total Revenue1,371.101,362.601,068.30758.601,031.40
Total Expenses566.80557.80571490.50573.40
Profit Before Tax818.20803.60477.60256.30439.60
Profit After Tax676.50668.50386.30212.70369
Operating Profit after Depreciation868.10852.90539.30305.10487.40

Particulars (in ₹ Cr.) 2024-09 2024-06 2024-03 2023-12 2023-09
Total Revenue1,292.601,236.90964.80625.30930.50
Total Expenses501.90473.90512.10387488.20
Profit Before Tax796.90758432.50223.60424
Profit After Tax661.10636.30349.10192360.20
Operating Profit after Depreciation842.10802.80488.60267.80467

Natco Pharma Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3
S1 1,233.25
S2 1,223.50
S3 1,207
Pivot 1,249.75
R1 1,259.50
R2 1,276
R3 1,285.75

Moving Average

20 SMA 1,310.71
50 SMA 1,369.94
100 SMA 1,408.29
200 SMA 1,288.43

Natco Pharma Ltd Corporate Actions

Natco Pharma Ltd

₹1.5/Share

Announcement Date 27 Nov 2024
Record Date 27 Nov 2024
Div Yield 75%

Natco Pharma Ltd Peer Comparison

Company Price Market Cap (in ₹ Cr)
Natco Pharma Ltd ₹1,243.35 ₹22,269.63
Sun Pharmaceuticals Industries Ltd ₹1,761.80 ₹4,22,714.84
Divis Laboratories Ltd ₹5,818.40 ₹1,54,460.24
Cipla Ltd ₹1,427.30 ₹1,15,270.75
Dr Reddys Laboratories Ltd ₹1,288.45 ₹1,07,511.36
Torrent Pharmaceuticals Ltd ₹3,157.60 ₹1,06,862.73

Natco Pharma Ltd News

Natco Pharma Ltd gains for third straight session

Natco Pharma Ltd is quoting at Rs 1479.3, up 2.32% on the day as on 12:49 IST on the NSE. The stock is up 93.42% in last one year as compared to a 13.26% jump in NIFTY and a 40.33% jump in the Nifty Pharma index.

19 Dec 2024, 01:05 pm

Natco Pharma Ltd soars 1.05%, Gains for third straight session

Natco Pharma Ltd is quoting at Rs 1429.95, up 1.05% on the day as on 12:49 IST on the NSE. The stock is up 80.52% in last one year as compared to a 18.09% gain in NIFTY and a 38.64% gain in the Nifty Pharma index.

03 Dec 2024, 01:06 pm

Natco Pharma sells Telangana land for Rs 116 crore

Natco Pharma informed that it has sold approximately 14.38 acres of land located at Mekaguda Gram Panchayat, Ranga Reddy District in Telangana for a total consideration of Rs 115.57 crore including certain infrastructure cost.

28 Nov 2024, 11:31 am

Natco Pharma submits ANDA with USFDA for Risdiplam for Oral solution

21 Nov 2024, 05:35 pm

Natco Pharma submits ANDA with US FDA for Risdiplam

Natco Pharma informed that it has submitted the abbreviated new drug application (ANDA) with the United States Food and Drug Administration (USFDA) for Risdiplam for oral solution.

21 Nov 2024, 03:00 pm

Natco Pharma Ltd Stock Analysis

  1. Annual revenue for Natco Pharma Ltd increased by 50.77% to ₹3,673.60 crore in FY 2024 from ₹2,436.50 crore in FY 2023.
  2. Annual Net Profit for Natco Pharma Ltd increased by 105.09% to ₹1,306.60 crore in FY 2024 from ₹637.10 crore in FY 2023.
  3. Promoter Shareholding in Natco Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 49.62% in September 2024 to 49.62% in December 2024.
  4. Natco Pharma Ltd delivered a 1-year return of 47.94% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
  5. Natco Pharma Ltd share price moved up by 1.60% from its previous close of INR ₹1,243. The latest Natco Pharma Ltd share price is INR ₹1,262.85.
  6. Natco Pharma Ltd share price today has been at a low of 1,233.30 and a high of 1,269.95. Over the past 52 weeks, the Natco Pharma Ltd share price has seen a low of 828 and a high of 1,639.

About Natco Pharma Ltd

Natco Pharma Ltd, founded in 1981, is a vertically integrated pharmaceutical company. It specialises in finished dosage formulations and active pharmaceutical ingredients. Headquartered in Hyderabad, Telangana, the company has carved a niche in complex products and therapeutic areas, particularly oncology. From modest beginnings, Natco has become a key player in the pharmaceutical industry, serving domestic and international markets.
 
Beyond pharmaceuticals, the company has diversified into agrochemicals, offering crop health sciences products. Its expertise lies in developing and marketing specialised medicines, contributing significantly to healthcare accessibility.

Over decades, Natco Pharma has consistently expanded its operations, solidifying its position as a crucial contributor to the pharmaceutical sector. As a result, it has established a reputation for innovation and quality. The company has a team of professional managerial promoters who are 
  • G S Murthy
  • V C Nannapaneni
  • Rajeev Nannapaneni
  • T V Rao
  • D G Prasad 

Natco Pharma, founded by V.C. Nannapaneni (holding 15.66% shares), has evolved into a prominent pharmaceutical company under his leadership. The company specialises in generic medicines. It strongly focuses on oncology, cardiology, and diabetology. Natco also produces agrochemicals, including insecticides.
 
It is not the top stock in the pharmaceutical sector. However, Natco Pharma maintains a robust market position. The company is known for innovative and affordable medicines. Its registered office is in Banjara Hills, Hyderabad, with its registrars also based in Hyderabad, Telangana.
 
Natco's journey from inception to global pharmaceutical leader is characterised by its unwavering commitment to innovation and quality. The company's strategic emphasis on complex products has been a key driver of its success in the pharmaceutical industry.
 
Throughout its growth, Natco has consistently expanded its product portfolio and market reach. This expansion, coupled with its focus on specialised therapeutic areas and complex formulations, has solidified Natco's position as a significant player in domestic and international pharmaceutical markets.

Impact of Natco Pharma Limited

Natco Pharma Ltd. has significantly impacted the pharmaceutical industry in India and globally. The company’s contributions span various aspects. It includes developing affordable medicines and efforts to improve public health. This impact results from Natco Pharma’s commitment to innovation and accessibility.
 
One of the most notable impacts of Natco Pharma is its role in making life-saving medications more affordable. The company has been at the forefront of producing generic versions of high-cost drugs. This is especially notable in the oncology segment. It has allowed patients to access important treatments at a fraction of the cost of branded medications. The availability of affordable generics has improved the quality of life for many patients.
 
Natco Pharma’s focus on oncology has been particularly impactful. The company has developed and launched several generic cancer drugs. These drugs have provided cost-effective alternatives to expensive branded medications. It also helps to contribute to the overall improvement in cancer care. The company’s efforts in this area have been recognised globally. Natco Pharma continues to be a key player in the oncology pharmaceutical market.
 
Natco Pharma’s impact extends beyond just providing medications. The company has invested in research and development to innovate and improve drug formulations. This focus on R&D has led to the development of new and improved medications that offer better efficiency and safety profiles. The company’s dedication to innovation ensures that it remains at the cutting edge of pharmaceutical advancements, continually bringing new solutions to the market.
 
The company’s efforts in the agrochemical sector also highlight its broader impact. Its crop health sciences division develops products that help improve agricultural productivity. These agrochemical products support farmers in protecting their crops from pests and diseases. As a result, Natco Pharma's products contribute to food security and agricultural sustainability. This diversification into agrochemicals demonstrates its commitment to addressing various societal needs through its expertise in chemical formulations.
 
Natco Pharma’s impact is also evident in its corporate social responsibility initiatives. The company actively engages in programs to improve education and community development. These initiatives are designed to uplift underprivileged communities and provide better opportunities and resources. Through its CSR efforts, Natco Pharma has made a positive difference in the lives of many individuals. This helps it to reinforce its role as a responsible corporate citizen.
 
The company’s global presence further amplifies its impact. Natco Pharma exports its products to numerous countries. Doing this ensures patients worldwide can access affordable and effective medications. This reach has positioned Natco Pharma as a significant player in the pharmaceutical industry, helping it to contribute to improved healthcare outcomes globally.

Natco Pharma Ltd. has profoundly impacted the pharmaceutical industry through its affordability, innovation, and quality commitment. The company’s efforts in developing generic medications, particularly in oncology, have made life-saving treatments accessible to many patients. Its ongoing dedication to improving healthcare outcomes ensures it will remain a vital player in its industry. This makes a positive difference in the lives of patients worldwide.

FAQ’s

What is the share price of Natco Pharma Ltd today?

Natco Pharma Ltd share price as on 22 Jan 2025 is ₹ 1262.85

What is the Market Cap of Natco Pharma Ltd?

The market cap of Natco Pharma Ltd stock is ₹22,263.36 Cr.

What is the PE Ratio of Natco Pharma Ltd?

The Price to Earnings (P/E) Ratio of Natco Pharma Ltd is 13.04

What is the PB Ratio of Natco Pharma Ltd?

The Price to Book (P/B) Ratio of Natco Pharma Ltd is 3.05

What is the 52 week high of Natco Pharma Ltd Share Price?

The 52 week high of Natco Pharma Ltd share price stands at ₹1,639

What is the 52 week low of Natco Pharma Ltd Share Price?

The 52 week low of Natco Pharma Ltd share price stands at ₹828

Get started with us today and
start building your wealth journey